This study is currently not recruiting participants.

6-Month Multicenter Randomized Open-Label Parallel-Group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-Month Safety Extension P

Investigation of Investigational Insulin Formulation for Effectiveness and Safety

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

This study is being done to compare the effectiveness, safety and tolerability of a newly developed formulation of insulin.

Detailed description of study

This study is being done to compare the effectiveness, safety and tolerability of a newly developed formulation of insulin.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Diabetes - Type II
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the effectiveness, safety, and tolerability of an investigational insulin formulation. Insulin is a hormone that helps control blood sugar levels in the body. This study aims to compare this new formulation with existing options to see how well it works and how safe it is for patients.

Participants in the study will receive either the investigational insulin formulation or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will monitor various health markers to assess the effects of the insulin formulation.

  • Who can participate: Eligibility criteria are not specified in the provided information. Please include age criteria and key eligibility factors if available.
  • Study details: Participants will receive either the investigational insulin formulation or a placebo. The study will monitor various health markers to assess the effects of the insulin formulation.
Updated on 19 Feb 2024. Study ID: 1110007042

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team